Regeneron Archives - Page 3 of 3 - Medical Design Sourcing

Researchers identify potent antibody cocktail to treat COVID-19

Researchers at the University of Maryland School of Medicine (UMSOM) said they identified a promising anti-viral cocktail therapy against COVID-19.

According to a news release, the researchers evaluated several human antibodies to determine the most potent combination to be mixed and used against SARS-CoV-2, the virus causing COVID-19. In collaboration with Regeneron Pharmaceuticals (NSDQ:REGN), UMSOM published results of a study in Science.

Just last week, Regeneron announced that it had initiated the first clinical trial of its dual antibody cocktail for preventing COVID-19, having already used the same “rapid response” approach to develop its REGN-EB3 antibody treatment for Ebola that is under review by the FDA.

The research was conducted using Regeneron’s proprietary genetically modified VelocImmune mice, which have a human immune system and antibodies isolated from humans who recovered from COVID-19. Researchers selected the most potent antibo…

Mayo Clinic launches test to detect COVID-19 immunity

Mayo Clinic announced that it launched a new SARS-CoV-2 neutralizing antibody test in support of efforts to establish therapies and vaccines for COVID-19.

As part of the Expanded Access Program for Convalescent Plasma and other critical research efforts, Mayo Clinic intends to make the test available to select labs, blood banks and biopharma clients later this month.

Mayo Clinic designed the new test to measure the level of neutralizing antibodies against SARS-CoV-2, the virus causing COVID-19. The test provides semi-quantitative detection of total neutralizing antibodies in human serum. After infection, most will develop an immune response to COVID-19, including the production of neutralizing antibodies against the SARS-CoV-2 spike glycoprotein. However, it’s currently unknown for how long the neutralizing antibodies persist after infection.

The test should only be ordered upon confirmation of prior infection and it should not be used to diagnose …

Regeneron launches clinical trial of COVID-19 antibody ‘cocktail’

Regeneron Pharmaceuticals (NSDQ:REGN) announced today that it initiated the first clinical trial of its dual antibody cocktail for preventing COVID-19.

The REGN-COV2 clinical program will include populations of hospitalized COVID-19 patients, non-hospitalized symptomatic COVID-19 patients, uninfected people in groups that have a high risk of exposure (healthcare workers or first responders, for example) and uninfected people with close exposure to a COVID-19 patient (such as a housemate). The placebo-controlled trials will be conducted at multiple sites, according to a news release.

Get the full story at our sister site, Drug Discovery & Development.

Regeneron launches clinical trial of COVID-19 antibody ‘cocktail’

Regeneron Pharmaceuticals (NSDQ:REGN) announced today that it initiated the first clinical trial of its dual antibody cocktail for preventing COVID-19.

The REGN-COV2 clinical program will include populations of hospitalized COVID-19 patients, non-hospitalized symptomatic COVID-19 patients, uninfected people in groups that have a high risk of exposure (healthcare workers or first responders, for example) and uninfected people with close exposure to a COVID-19 patient (such as a housemate). The placebo-controlled trials will be conducted at multiple sites, according to a news release.

Using its proprietary genetically modified VelocImmune mice, which have a human immune system and antibodies isolated from humans who recovered from COVID-19, Regeneron scientists evaluated thousands of fully human antibodies. They then selected the two most potent, non-competing and virus-neutralizing antibodies and scaled them up for clinical use. The antibodies bind non-competiti…